We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,178.00
Bid: 12,178.00
Ask: 12,180.00
Change: 8.00 (0.07%)
Spread: 2.00 (0.016%)
Open: 12,114.00
High: 12,258.00
Low: 12,114.00
Prev. Close: 12,170.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Canada to shrug off 'momentary disruptions' in vaccine supply, working closely with U.S. - Trudeau

Thu, 04th Feb 2021 19:54

(Recasts with comments by Prime Minister Trudeau)

By Steve Scherer and Allison Martell

OTTAWA, Feb 4 (Reuters) - Canada will succeed in inoculating
its population despite "momentary disruptions" in the supply of
COVID-19 vaccines and is working closely with the new U.S.
administration to fight the disease, Prime Minister Justin
Trudeau said on Thursday.

Trudeau's Liberal government is under pressure over the slow
roll out of the vaccination program, caused in part by Pfizer
Inc temporarily cutting its promised deliveries and a
temporary slowdown of Moderna Inc doses.

"Obviously with this global supply chain around new products
and manufacturing scale-ups ... there are momentary disruptions
week over week. But we're still very much on track to get the
commitments fulfilled and get many vaccines to Canadians as
quickly as possible," Trudeau said in an interview.

Trudeau promised that tens of millions of doses would arrive
in the months to come and reiterated that every Canadian seeking
inoculation would be vaccinated by September.

As part of a bid to contain the spread of the disease,
Canada and the United States have closed their joint border to
non-essential travel. Trudeau said he and new U.S. President Joe
Biden agreed on a joint approach to fighting COVID-19.

"We're working very, very closely on all aspects of it from
borders to scientific research to indeed vaccines," he said.

"Our conversations are going to continue with the U.S. on
supply chains," he said, without giving details. Last year,
tensions arose between Canada and the administration of then
President Donald Trump over delays in the supply of personal
protective equipment.

Last year Trump also signed an executive order aimed at
keeping U.S.-produced vaccines in the United States. Trudeau did
not give a direct answer when asked whether he would press Biden
to scrap the order.

Canada does not yet have a vaccine manufacturing facility of
its own and is reliant on foreign suppliers.

Separately, federal Procurement Minister Anita Anand said
deliveries of AstraZeneca Plc's COVID-19 vaccine could
begin before the end of March, if Canada's health regulator
approves its use.

AstraZeneca Canada filed a rolling application for its
vaccine with Health Canada in October and is waiting for
approval from the drug regulator. Health Canada is expected to
complete its review soon.

In a separate briefing, federal officials confirmed Canada's
most recent shipment of Moderna Inc's COVID-19 vaccine
contained 22% fewer doses than originally expected and said the
next shipment, due in three weeks, would also be short.

Fortin added Moderna was working in "good faith" to deliver
those doses as quickly as possible to Canada and noted the
obstacles would be temporary.

Shipments of Pfizer Inc's vaccine, meanwhile, are
expected to ramp up later this month.

Trudeau's government is also facing criticism over tapping
into COVAX, a global vaccine-sharing initiative meant to help
low-income countries buy doses. Canada will get 1.9 million
AstraZeneca doses from the initiative.

"Our government will never apologize for doing everything
possible to get Canadians vaccinated as quickly as possible,"
Deputy Prime Minister Chrystia Freeland told lawmakers.
(Reporting by Steve Scherer in Ottawa and Allison Martell in
Toronto; Additional reporting by David Ljunggren and Julie
Gordon in Ottawa; Editing by Mark Potter and Daniel Wallis)

More News
Today 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
Today 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.